Nephrectomy

The FDA expanded the approval of pembrolizumab to include adjuvant treatment of certain patients with renal cell carcinoma.

Nivolumab plus cabozantinib improved outcomes compared with sunitinib regardless of prior nephrectomy among patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Post-nephrectomy recurrence appeared associated with shorter survival among patients with intermediate-high or high-risk renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.